Federated Hermes’s Takeda Pharmaceutical TAK Stock Holding History

Federated Hermes’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.04M	Sell	376,858 -5,393	-1%	-$89.2K	0.01%	803
2026 Q1	$7.08M	Buy	382,251 +5,388	+1%	+$94.6K	0.01%	733
2025 Q4	$5.88M	Sell	376,863 -21,523	-5%	-$308K	0.01%	751
2025 Q3	$5.83M	Sell	398,386 -135,641	-25%	-$2.01M	0.01%	706
2025 Q2	$8.26M	Sell	534,027 -7,892	-1%	-$117K	0.02%	615
2025 Q1	$8.06M	Buy	541,919 +106,885	+25%	+$1.5M	0.02%	605
2024 Q4	$5.76M	Sell	435,034 -107,719	-20%	-$1.48M	0.01%	671
2024 Q3	$7.72M	Buy	542,753 +161,880	+43%	+$2.3M	0.02%	623
2024 Q2	$4.93M	Sell	380,873 -209,700	-36%	-$2.78M	0.01%	718
2024 Q1	$8.2M	Buy	590,573 +152,249	+35%	+$2.21M	0.02%	607
2023 Q4	$6.25M	Sell	438,324 -125,449	-22%	-$1.78M	0.02%	668
2023 Q3	$8.72M	Sell	563,773 -18,089	-3%	-$280K	0.02%	566
2023 Q2	$9.14M	Sell	581,862 -19,767	-3%	-$324K	0.02%	562
2023 Q1	$9.91M	Buy	601,629 +310,512	+107%	+$4.95M	0.02%	547
2022 Q4	$4.54M	Buy	+291,117	New	+$4.07M	0.01%	702

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Federated Hermes's TAK Position: Q2 2026 in Review

Federated Hermes reduced its Takeda Pharmaceutical (TAK) stake by 1.4% in Q2 2026, selling an estimated $89.2K and leaving 376,858 shares worth $6.04M. The position accounts for 0.01% of the portfolio, ranked #803.

Federated Hermes first reported a position in TAK in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.91M in Q1 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Federated Hermes held 376,858 shares of Takeda Pharmaceutical worth $6.04M as of Q2 2026.
Federated Hermes sold 5,393 Takeda Pharmaceutical shares in Q2 2026, an estimated $89.2K.
Takeda Pharmaceutical made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #803 holding.
Federated Hermes first reported a position in Takeda Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
Federated Hermes's Takeda Pharmaceutical position peaked at $9.91M in Q1 2023.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.